Investing.com -- Swiss pharmaceutical giant Novartis (SIX: NOVN ) plans to begin mass production of radiopharmaceuticals in Japan by 2026, according to Nikkei . Radiopharmaceuticals, considered a next-generation cancer treatment, are currently produced by Novartis in Europe and the U.S., and then exported to Japan.

The company’s strategy involves installing new production equipment at its facility located in Tamba-Sasayama, in Hyogo prefecture. This move will establish the first mass production facility for radiopharmaceuticals in Japan.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.